There are so many conflicting studies and concerns about hormone treatment in post-menopausal women. It gives relief to some, increases risks in others, and is a decision every woman and her doctor has to make on an individual basis -- What are the risks and benefits to me?
A new analysis from the Women's Health Initiative clinical trial presented at the 31st Annual San Antonio Breast Cancer Symposium discusses those risks, and shows that it's important to re-evaluation hormonal therapy from time to time. It says that stopping combined estrogen-plus-progestin hormone therapy in postmenopausal women who have a uterus helps their increased risk for breast cancer decline again.
"The risk goes away quickly," said researcher Roman Chlebowski, MD, PhD, from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in California. He said it takes about two years for a woman's risk to return to "baseline," or where she was before she began therapy.
Here's the complete story:
http://www.medscape.com/viewarticle/585377